This study evaluated the safety of using radiation therapy concurrently with CDK4/6 inhibitors to treat 133 patients with metastatic hormone receptor-positive breast cancer. The study found that using radiation therapy concurrently did not significantly increase adverse events grades 3 or higher, any grade toxicity, rates of dose reduction or discontinuation of CDK4/6 inhibitors. Additionally, concurrent radiation therapy did not negatively impact progression-free or overall survival rates. The results suggest radiation therapy can be safely combined with CDK4/6 inhibitors without increasing toxicity or interfering with systemic treatment.
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
5416- CDK4.pptx
1. Safety of CDK4/6 inhibitors and
concomitant radiation therapy in
patients affected by metastatic breast
cancer
2. • Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for
the initial treatment of patients with metastatic hormone receptor-positive/human
epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.
• Aim of the study
• To evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive
series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the
metastatic setting.
Background
Visani L, et al. Radiotherapy and Oncology. 2022 Oct 28.
3. • From September 2017 to February 2020, we collected and analysed a sequential series of
patients with metastatic disease treated with CDK4/6i, receiving RT or not, at two European
institutions.
• Primary outcomes of the study were
• the impact of concomitant RT on any toxicity (any grade),
• any adverse events (AEs) ≥G3,
• CDK4/6i dose reduction rate, and
• CDK4/6i treatment discontinuation rate.
Methods
Visani L, et al. Radiotherapy and Oncology. 2022 Oct 28.
4. • Total of 133 consecutive patients.
• The median age of the patients was 59 years (range 37-86).
• Concomitant RT administration was not significantly related to higher AEs ≥G3 (p=0.45) and
any grade toxicity (p=0.69); there was no association with RT and CDK4/6i dose reductions
(p=1.0) and discontinuations (p=0.07).
• At a median duration of follow-up of 18.8 months,
• The progression-free survival (PFS) rate was 65.0% and
• the overall survival (OS) rate was 38.7% in the whole group.
• The use of concomitant RT did not affect both PFS (p=0.71) and OS rates (p=0.55).
Results
Visani L, et al. Radiotherapy and Oncology. 2022 Oct 28.
6. • Our data are encouraging regarding the safety of this combination, showing that concurrent
RT did not have an impact on systemic treatment conduction and did not increase toxicity.
Conclusion
Visani L, et al. Radiotherapy and Oncology. 2022 Oct 28.
